Tenascin C、vimentin和PI3K在三阴性乳腺癌中的表达及其临床意义分析  

Expression and clinical significance of tenascin C,vimentin and PI3K in triple negative breast cancer

作　　者：胡红光[1] 赵敏[1] 黄金[1] HU Hong-guang;ZHAO Min;HUANG Jin(Department of Pathology,Hefei Second People's Hospital,Hefei 230011,China)

机构地区：[1]合肥市第二人民医院病理科,合肥230011

出　　处：《中国医学前沿杂志（电子版）》2020年第1期109-113,共5页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的探讨tenascin C、波形蛋白(vimentin)和磷脂酰肌醇3-激酶(phosphatidylin-ositol-3-kinase,PI3K)在三阴性乳腺癌(triple negative breast cancer,TNBC)中的表达及其临床意义。方法选取1993年1月至2018年12月合肥市第二人民医院收治的39例TNBC患者为研究对象,将其纳入TNBC组,并随机选取同期合肥市第二人民医院收治的50例非TNBC乳腺癌患者纳入非TNBC组。采用免疫组织化学染色法检测全部患者癌组织中tenascin C、vimentin和PI3K的表达水平,并分析其与TNBC患者临床病理特征和预后的相关性。结果TNBC组患者癌组织中tenascin C阳性表达率显著高于非TNBC组(P<0.05),而两组患者癌组织中vimentin、PI3K阳性表达率比较差异均无统计学意义(均P>0.05)。TNBC组肿瘤浸润深度T3~T4患者癌组织中vimentin和PI3K阳性表达率均显著高于肿瘤浸润深度T1~T2患者(均P<0.05),淋巴结转移患者癌组织中vimentin阳性表达率显著高于无淋巴结转移患者(P<0.05),tenascin C阳性表达率与TNBC患者各临床病理特征均无明显相关性(均P>0.05)。全部TNBC患者共随访4~83个月,中位生存时间为37.3个月,其中1年和3年生存率分别为89.7%和53.8%。vimentin阳性表达患者中位生存时间显著短于vimentin阴性表达患者(P<0.05),tenascin C、PI3K阳性和阴性表达患者的中位生存时间比较差异均无统计学意义(均P>0.05)。多因素Cox比例风险回归模型分析结果表明,淋巴结转移、癌组织中vimentin阳性表达均为TNBC患者死亡的独立危险因素(均P<0.05)。结论TNBC患者癌组织中tenascin C阳性表达率显著升高,vimentin和PI3K可能参与了TNBC的肿瘤侵袭与转移,其中癌组织中vimentin阳性表达是患者死亡的独立危险因素。Objective To investigate the expression and clinical significance of tenascin C,vimentin and phosphatidylin-ositol-3-kinase(PI3K)in triple negative breast cancer(TNBC).Method Thirty-nine patients with TNBC admitted to Hefei Second People's Hospital from January 1993 to December 2018 were enrolled for the study as TNBC group,and 50 patients with non-TNBC admitted to Hefei Second People's Hospital during the same period were randomly selected as non-TNBC group.Immunohistochemical staining was performed to detect the expression levels of tenascin C,vimentin and PI3K in cancer tissues of all patients,and their correlation with clinicopathological features and prognosis of TNBC patients were analyzed.Result The positive expression rate of tenascin C in cancer tissues of TNBC group was significantly higher than that in non-TNBC group(P<0.05).There were no significant differences in the positive expression rates of vimentin and PI3K in cancer tissues between the two groups(all P>0.05).The positive expression rates of vimentin and PI3K in cancer tissues of patients with tumor infiltration depth T3~T4 in TNBC group were significantly higher than those of patients with tumor infiltration depth T1~T2(all P<0.05).The positive expression rate of vimentin in cancer tissues of patients with lymph node metastasis was significantly higher than that of patients without lymph node metastasis(all P<0.05).The positive expression rate of tenascin C had no obvious correlation with clinical pathological features of TNBC patients(all P>0.05).All patients with TNBC were followed up for 4~83 months,and their median survival time was 37.3 months.The 1 year and 3 years survival rates were 89.7%and 53.8%respectively.The median survival time of patients with positive expression of vimentin was significantly shorter than that of patients with negative expression of vimentin(P<0.05),there were no significant differences in median survival time between patients with positive and negative expression of tenascin C and PI3K(all P>0.05).Multivariate

关 键 词：三阴性乳腺癌 Tenascin C 波形蛋白 磷脂酰肌醇3-激酶 预后 

分 类 号：R737.9[医药卫生—肿瘤]